| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Elongation Factor 2 Kinase | 21 | 2022 | 44 | 7.970 |
Why?
|
| Triple Negative Breast Neoplasms | 13 | 2023 | 1215 | 3.220 |
Why?
|
| Forkhead Box Protein M1 | 7 | 2023 | 113 | 3.110 |
Why?
|
| RNA, Small Interfering | 24 | 2022 | 2216 | 2.640 |
Why?
|
| Cell Proliferation | 30 | 2023 | 7226 | 2.260 |
Why?
|
| MicroRNAs | 15 | 2024 | 2947 | 2.240 |
Why?
|
| Autophagy | 18 | 2021 | 927 | 2.010 |
Why?
|
| Integrin beta1 | 4 | 2021 | 126 | 1.820 |
Why?
|
| RNA Interference | 10 | 2022 | 1408 | 1.710 |
Why?
|
| Leukemia, Promyelocytic, Acute | 7 | 2019 | 430 | 1.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2022 | 8873 | 1.620 |
Why?
|
| Signal Transduction | 31 | 2022 | 11965 | 1.620 |
Why?
|
| Pancreatic Neoplasms | 11 | 2022 | 5061 | 1.600 |
Why?
|
| Cell Line, Tumor | 51 | 2023 | 14551 | 1.490 |
Why?
|
| Cell Movement | 11 | 2022 | 2466 | 1.160 |
Why?
|
| RNAi Therapeutics | 3 | 2022 | 42 | 1.120 |
Why?
|
| Tretinoin | 7 | 2008 | 623 | 1.110 |
Why?
|
| Liposomes | 13 | 2022 | 684 | 1.100 |
Why?
|
| src-Family Kinases | 6 | 2021 | 478 | 1.080 |
Why?
|
| Carcinogenesis | 7 | 2022 | 1026 | 1.030 |
Why?
|
| Receptor, Serotonin, 5-HT1D | 2 | 2014 | 2 | 1.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 2 | 2014 | 9 | 1.020 |
Why?
|
| Apoptosis | 18 | 2023 | 7591 | 0.980 |
Why?
|
| Ferric Compounds | 2 | 2024 | 73 | 0.970 |
Why?
|
| Gene Silencing | 7 | 2019 | 837 | 0.950 |
Why?
|
| Ovarian Neoplasms | 16 | 2021 | 4638 | 0.940 |
Why?
|
| Nanoparticles | 12 | 2022 | 554 | 0.920 |
Why?
|
| Neoplasms | 14 | 2024 | 15193 | 0.910 |
Why?
|
| Leiomyoma | 3 | 2022 | 145 | 0.880 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 2864 | 0.860 |
Why?
|
| Flavonoids | 1 | 2023 | 188 | 0.860 |
Why?
|
| Transglutaminases | 3 | 2014 | 99 | 0.850 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2021 | 703 | 0.830 |
Why?
|
| Benzoquinones | 2 | 2021 | 108 | 0.820 |
Why?
|
| Focal Adhesion Kinase 1 | 3 | 2017 | 111 | 0.810 |
Why?
|
| Hyaluronic Acid | 2 | 2020 | 168 | 0.810 |
Why?
|
| Beclin-1 | 8 | 2021 | 85 | 0.800 |
Why?
|
| Integrin beta3 | 1 | 2021 | 44 | 0.780 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 3230 | 0.780 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2022 | 1724 | 0.770 |
Why?
|
| Pancreas | 2 | 2014 | 718 | 0.760 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2021 | 96 | 0.760 |
Why?
|
| Mice, Nude | 15 | 2022 | 4307 | 0.730 |
Why?
|
| Neoplastic Stem Cells | 4 | 2017 | 1443 | 0.710 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 311 | 0.690 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 661 | 0.680 |
Why?
|
| Drug Delivery Systems | 7 | 2020 | 669 | 0.670 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 3 | 2017 | 107 | 0.650 |
Why?
|
| Humans | 100 | 2024 | 261506 | 0.650 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 771 | 0.640 |
Why?
|
| Up-Regulation | 5 | 2022 | 2450 | 0.640 |
Why?
|
| Piperidines | 1 | 2023 | 1035 | 0.630 |
Why?
|
| Molecular Targeted Therapy | 7 | 2021 | 2330 | 0.630 |
Why?
|
| Animals | 52 | 2022 | 59536 | 0.610 |
Why?
|
| Cell Survival | 11 | 2021 | 3045 | 0.590 |
Why?
|
| Serotonin 5-HT1 Receptor Antagonists | 1 | 2016 | 1 | 0.590 |
Why?
|
| Neoplasm Invasiveness | 7 | 2021 | 3981 | 0.570 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 15694 | 0.570 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2023 | 4757 | 0.560 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 493 | 0.560 |
Why?
|
| Oxadiazoles | 1 | 2016 | 57 | 0.560 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 479 | 0.550 |
Why?
|
| MCF-7 Cells | 6 | 2021 | 550 | 0.550 |
Why?
|
| Uterine Neoplasms | 2 | 2020 | 545 | 0.550 |
Why?
|
| Oxides | 4 | 2009 | 211 | 0.520 |
Why?
|
| Arsenicals | 4 | 2009 | 201 | 0.520 |
Why?
|
| RNA, Untranslated | 3 | 2022 | 237 | 0.510 |
Why?
|
| Mice | 34 | 2022 | 34495 | 0.500 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 96 | 0.500 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2005 | 200 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2020 | 3821 | 0.490 |
Why?
|
| Glioblastoma | 2 | 2023 | 1797 | 0.490 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 821 | 0.480 |
Why?
|
| Antineoplastic Agents | 17 | 2021 | 14289 | 0.470 |
Why?
|
| Microtubule-Associated Proteins | 5 | 2021 | 534 | 0.450 |
Why?
|
| Phthalazines | 1 | 2015 | 253 | 0.450 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 358 | 0.450 |
Why?
|
| Exosomes | 5 | 2020 | 253 | 0.440 |
Why?
|
| Drug Carriers | 6 | 2020 | 327 | 0.440 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 1823 | 0.440 |
Why?
|
| Cellular Reprogramming | 1 | 2015 | 189 | 0.440 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 1390 | 0.430 |
Why?
|
| Biological Assay | 3 | 2016 | 177 | 0.390 |
Why?
|
| Benzamides | 1 | 2016 | 1832 | 0.380 |
Why?
|
| Leukemia, Myeloid | 2 | 2007 | 941 | 0.380 |
Why?
|
| Protein Kinase C-delta | 2 | 2007 | 42 | 0.370 |
Why?
|
| Female | 46 | 2022 | 141928 | 0.360 |
Why?
|
| Nanocapsules | 1 | 2010 | 28 | 0.360 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2014 | 621 | 0.360 |
Why?
|
| Granulocytes | 2 | 2008 | 224 | 0.360 |
Why?
|
| Peroxiredoxins | 1 | 2009 | 17 | 0.350 |
Why?
|
| Down-Regulation | 5 | 2017 | 2074 | 0.350 |
Why?
|
| Acetophenones | 4 | 2014 | 19 | 0.340 |
Why?
|
| Benzopyrans | 4 | 2014 | 41 | 0.340 |
Why?
|
| RNA, Messenger | 8 | 2021 | 6150 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 5178 | 0.340 |
Why?
|
| Unfolded Protein Response | 2 | 2019 | 115 | 0.340 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2022 | 973 | 0.330 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 726 | 0.330 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2008 | 58 | 0.330 |
Why?
|
| Doxorubicin | 2 | 2013 | 3005 | 0.330 |
Why?
|
| Cyclin D1 | 4 | 2022 | 576 | 0.330 |
Why?
|
| Lipids | 2 | 2022 | 644 | 0.310 |
Why?
|
| Blotting, Western | 7 | 2017 | 3536 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 1493 | 0.310 |
Why?
|
| Genes, myc | 1 | 2009 | 358 | 0.310 |
Why?
|
| Receptor, Notch1 | 2 | 2021 | 218 | 0.290 |
Why?
|
| Oncogenes | 2 | 2021 | 673 | 0.280 |
Why?
|
| Cell Differentiation | 5 | 2019 | 4078 | 0.280 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4849 | 0.280 |
Why?
|
| Piperazines | 1 | 2015 | 2101 | 0.280 |
Why?
|
| Macrophages | 3 | 2021 | 1304 | 0.280 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 674 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2016 | 3639 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 2359 | 0.270 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2004 | 365 | 0.270 |
Why?
|
| HL-60 Cells | 4 | 2008 | 302 | 0.260 |
Why?
|
| Prostatic Neoplasms | 6 | 2021 | 5767 | 0.250 |
Why?
|
| Transfection | 6 | 2017 | 2944 | 0.250 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 10331 | 0.250 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2019 | 425 | 0.250 |
Why?
|
| RNA-Binding Proteins | 2 | 2008 | 984 | 0.250 |
Why?
|
| Structure-Activity Relationship | 3 | 2021 | 931 | 0.240 |
Why?
|
| Cell Adhesion | 2 | 2019 | 1008 | 0.240 |
Why?
|
| Fenretinide | 1 | 2004 | 96 | 0.240 |
Why?
|
| Tissue Distribution | 2 | 2024 | 875 | 0.240 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2019 | 1064 | 0.240 |
Why?
|
| Vaccines, DNA | 2 | 2001 | 105 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2019 | 1546 | 0.220 |
Why?
|
| Metergoline | 1 | 2022 | 2 | 0.220 |
Why?
|
| Endoribonucleases | 1 | 2023 | 107 | 0.220 |
Why?
|
| Mutation | 5 | 2023 | 15179 | 0.220 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2003 | 62 | 0.210 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2019 | 486 | 0.210 |
Why?
|
| Polyethyleneimine | 2 | 2019 | 18 | 0.210 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11538 | 0.210 |
Why?
|
| Luminescent Measurements | 2 | 2013 | 148 | 0.210 |
Why?
|
| Heterografts | 3 | 2022 | 733 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 3 | 2020 | 1547 | 0.210 |
Why?
|
| AIDS Vaccines | 2 | 2003 | 78 | 0.210 |
Why?
|
| Carbon Cycle | 1 | 2021 | 5 | 0.210 |
Why?
|
| Helicobacter pylori | 3 | 2000 | 1295 | 0.200 |
Why?
|
| Helicobacter Infections | 3 | 2000 | 1216 | 0.200 |
Why?
|
| Activating Transcription Factor 4 | 2 | 2019 | 73 | 0.200 |
Why?
|
| Endothelial Cells | 2 | 2020 | 1048 | 0.200 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2022 | 131 | 0.200 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2021 | 72 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 657 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5112 | 0.200 |
Why?
|
| Transcription Factor HES-1 | 1 | 2021 | 49 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2019 | 755 | 0.200 |
Why?
|
| Carcinoma | 4 | 2015 | 2578 | 0.200 |
Why?
|
| Serotonin | 1 | 2022 | 264 | 0.200 |
Why?
|
| GTP-Binding Proteins | 3 | 2014 | 321 | 0.200 |
Why?
|
| Androstenes | 1 | 2021 | 41 | 0.200 |
Why?
|
| Jagged-1 Protein | 1 | 2021 | 101 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 538 | 0.190 |
Why?
|
| Macrophage Activation | 1 | 2021 | 148 | 0.190 |
Why?
|
| Influenza A virus | 1 | 2021 | 270 | 0.180 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 3 | 2005 | 18 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2020 | 460 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 7789 | 0.180 |
Why?
|
| Immunotherapy | 4 | 2023 | 3341 | 0.180 |
Why?
|
| Transcription Factors | 3 | 2022 | 5270 | 0.170 |
Why?
|
| Cell Communication | 2 | 2020 | 509 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 480 | 0.170 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2019 | 11 | 0.170 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 146 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 6 | 2019 | 1077 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 3203 | 0.170 |
Why?
|
| Nanomedicine | 3 | 2019 | 54 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2012 | 2054 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2012 | 287 | 0.170 |
Why?
|
| Sucrose | 1 | 2019 | 64 | 0.170 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 108 | 0.170 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 85 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 129 | 0.170 |
Why?
|
| Genistein | 1 | 2019 | 73 | 0.170 |
Why?
|
| Osteolysis | 1 | 2019 | 80 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 204 | 0.160 |
Why?
|
| Enzyme Activation | 2 | 2020 | 1764 | 0.160 |
Why?
|
| Phosphorylation | 5 | 2020 | 4804 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 164 | 0.160 |
Why?
|
| HIV Antigens | 1 | 1998 | 24 | 0.160 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2017 | 494 | 0.160 |
Why?
|
| A549 Cells | 1 | 2018 | 124 | 0.160 |
Why?
|
| Dioxygenases | 1 | 2019 | 159 | 0.160 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 411 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 280 | 0.160 |
Why?
|
| Histone Demethylases | 1 | 2019 | 144 | 0.150 |
Why?
|
| Triterpenes | 1 | 2017 | 61 | 0.150 |
Why?
|
| Proteolysis | 1 | 2019 | 370 | 0.150 |
Why?
|
| HIV Antibodies | 1 | 1998 | 102 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2018 | 204 | 0.150 |
Why?
|
| Models, Biological | 6 | 2019 | 3254 | 0.150 |
Why?
|
| Spheroids, Cellular | 2 | 2015 | 222 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2015 | 256 | 0.150 |
Why?
|
| Lysosomes | 1 | 2019 | 347 | 0.150 |
Why?
|
| Curcumin | 1 | 2017 | 117 | 0.150 |
Why?
|
| Benzyl Alcohols | 1 | 2017 | 33 | 0.150 |
Why?
|
| Stomach | 1 | 2000 | 387 | 0.150 |
Why?
|
| Protein Conformation | 1 | 2020 | 1258 | 0.150 |
Why?
|
| Theranostic Nanomedicine | 1 | 2016 | 14 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 1998 | 355 | 0.140 |
Why?
|
| Disease Progression | 4 | 2022 | 6682 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2020 | 1987 | 0.140 |
Why?
|
| Disease Models, Animal | 7 | 2022 | 7222 | 0.140 |
Why?
|
| Receptor, EphB4 | 1 | 2015 | 27 | 0.140 |
Why?
|
| Diphosphonates | 2 | 2015 | 262 | 0.130 |
Why?
|
| Cell Line | 3 | 2016 | 5114 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 2 | 2015 | 216 | 0.130 |
Why?
|
| Metal Nanoparticles | 1 | 2017 | 164 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 2015 | 34 | 0.130 |
Why?
|
| Gold | 1 | 2017 | 270 | 0.130 |
Why?
|
| Mitogens | 1 | 2015 | 75 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 436 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2022 | 1216 | 0.130 |
Why?
|
| Anoikis | 1 | 2015 | 63 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 615 | 0.130 |
Why?
|
| Oligonucleotides | 1 | 2016 | 227 | 0.130 |
Why?
|
| Claudin-1 | 1 | 2014 | 32 | 0.130 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2015 | 30 | 0.130 |
Why?
|
| Protein Kinases | 2 | 2010 | 874 | 0.130 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 120 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 231 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2014 | 33 | 0.120 |
Why?
|
| Gene Expression | 2 | 2020 | 3570 | 0.120 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2012 | 161 | 0.120 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2014 | 76 | 0.120 |
Why?
|
| Calmodulin | 2 | 2012 | 241 | 0.120 |
Why?
|
| Erythropoietin | 1 | 2015 | 205 | 0.120 |
Why?
|
| Biological Products | 1 | 2017 | 274 | 0.120 |
Why?
|
| Receptors, Prolactin | 1 | 2014 | 27 | 0.120 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2014 | 19 | 0.120 |
Why?
|
| Oxidoreductases | 1 | 2015 | 171 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2021 | 925 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2023 | 2488 | 0.120 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2014 | 52 | 0.120 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2014 | 159 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2015 | 132 | 0.120 |
Why?
|
| Prolactin | 1 | 2014 | 155 | 0.120 |
Why?
|
| Cadherins | 2 | 2014 | 660 | 0.120 |
Why?
|
| Cytokines | 1 | 2003 | 2809 | 0.120 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2004 | 95 | 0.120 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 181 | 0.110 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.110 |
Why?
|
| beta Catenin | 2 | 2015 | 688 | 0.110 |
Why?
|
| CD24 Antigen | 1 | 2013 | 85 | 0.110 |
Why?
|
| Kallikreins | 1 | 2013 | 84 | 0.110 |
Why?
|
| Integrins | 1 | 2014 | 262 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 203 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2015 | 485 | 0.110 |
Why?
|
| Genes, src | 1 | 2012 | 27 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 4 | 2021 | 5395 | 0.110 |
Why?
|
| Recombinant Proteins | 3 | 2015 | 2927 | 0.110 |
Why?
|
| Base Sequence | 2 | 2009 | 4917 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.100 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2011 | 27 | 0.100 |
Why?
|
| Threonine | 1 | 2012 | 161 | 0.100 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Mitochondria | 1 | 2019 | 1282 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2012 | 82 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2022 | 2295 | 0.100 |
Why?
|
| Cisplatin | 1 | 2019 | 2432 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 4938 | 0.100 |
Why?
|
| Mice, SCID | 3 | 2020 | 1869 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 4367 | 0.100 |
Why?
|
| Thrombocytosis | 1 | 2012 | 121 | 0.100 |
Why?
|
| Membrane Proteins | 4 | 2015 | 2819 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2015 | 1996 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 670 | 0.090 |
Why?
|
| Serine | 1 | 2012 | 388 | 0.090 |
Why?
|
| Urease | 2 | 2000 | 60 | 0.090 |
Why?
|
| Acute Disease | 2 | 2007 | 2422 | 0.090 |
Why?
|
| Androgens | 1 | 2013 | 511 | 0.090 |
Why?
|
| Imidazoles | 2 | 2015 | 999 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2014 | 475 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2021 | 515 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 131 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3101 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 366 | 0.090 |
Why?
|
| Diet | 1 | 2017 | 1440 | 0.090 |
Why?
|
| Ki-67 Antigen | 2 | 2022 | 666 | 0.080 |
Why?
|
| Plasmids | 1 | 2011 | 837 | 0.080 |
Why?
|
| Tamoxifen | 1 | 2013 | 876 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1143 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 1213 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 987 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.080 |
Why?
|
| Prognosis | 3 | 2022 | 21713 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 1062 | 0.080 |
Why?
|
| HEK293 Cells | 3 | 2019 | 1489 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4557 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1129 | 0.080 |
Why?
|
| Calcium | 2 | 2012 | 1537 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 1656 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2008 | 92 | 0.080 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 518 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 2008 | 149 | 0.080 |
Why?
|
| Protein Transport | 2 | 2007 | 734 | 0.080 |
Why?
|
| Eukaryotic Cells | 1 | 2007 | 45 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5319 | 0.080 |
Why?
|
| Chickens | 2 | 2019 | 523 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2002 | 489 | 0.080 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 7548 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1038 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 519 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 889 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 1399 | 0.070 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2019 | 61 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 904 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 203 | 0.070 |
Why?
|
| Peptides | 3 | 2021 | 1479 | 0.070 |
Why?
|
| Isomerism | 1 | 2005 | 63 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 566 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2011 | 1678 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 6009 | 0.070 |
Why?
|
| Particle Size | 2 | 2017 | 182 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2022 | 1313 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 383 | 0.070 |
Why?
|
| Gene Transfer Techniques | 2 | 2019 | 716 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 482 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5539 | 0.060 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2004 | 42 | 0.060 |
Why?
|
| Vaccination | 2 | 2001 | 1123 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 6207 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 4821 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 6942 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2004 | 154 | 0.060 |
Why?
|
| Lymphoma | 1 | 2002 | 1467 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 15862 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2019 | 2084 | 0.060 |
Why?
|
| Albumins | 2 | 2015 | 258 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 788 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 1399 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 2314 | 0.050 |
Why?
|
| Drug Design | 2 | 2015 | 375 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 2013 | 549 | 0.050 |
Why?
|
| Stem Cell Niche | 1 | 2022 | 94 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 144 | 0.050 |
Why?
|
| Simvastatin | 1 | 2022 | 106 | 0.050 |
Why?
|
| Male | 10 | 2021 | 123000 | 0.050 |
Why?
|
| Cell Death | 2 | 2014 | 671 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 4233 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 275 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2015 | 1082 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 1320 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 1998 | 385 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2000 | 63 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2020 | 70 | 0.050 |
Why?
|
| Cell Plasticity | 1 | 2021 | 66 | 0.050 |
Why?
|
| Coumarins | 1 | 2020 | 33 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2000 | 93 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2000 | 63 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 6089 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 149 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1620 | 0.050 |
Why?
|
| Cobalt | 1 | 2019 | 55 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2020 | 111 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 448 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 110 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2019 | 34 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 3869 | 0.040 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2019 | 13 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 471 | 0.040 |
Why?
|
| Porosity | 1 | 2019 | 56 | 0.040 |
Why?
|
| Static Electricity | 1 | 2019 | 58 | 0.040 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2003 | 1544 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 260 | 0.040 |
Why?
|
| Hemolysis | 1 | 2019 | 127 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 208 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 314 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 281 | 0.040 |
Why?
|
| Kinetics | 2 | 2012 | 2049 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 360 | 0.040 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2017 | 14 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 153 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 104 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 703 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1998 | 88 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2002 | 612 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 905 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2017 | 12 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2000 | 558 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 204 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2001 | 1144 | 0.040 |
Why?
|
| Rhizome | 1 | 2017 | 6 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 506 | 0.040 |
Why?
|
| Surface Properties | 1 | 2017 | 180 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 1998 | 202 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 2017 | 44 | 0.040 |
Why?
|
| Proteomics | 1 | 2004 | 1380 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.040 |
Why?
|
| Morpholinos | 1 | 2016 | 15 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2019 | 362 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2021 | 1732 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 745 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 613 | 0.030 |
Why?
|
| Receptors, Erythropoietin | 1 | 2015 | 70 | 0.030 |
Why?
|
| FMN Reductase | 1 | 2015 | 9 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 598 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 2803 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2017 | 215 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 1070 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2015 | 122 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 107 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1998 | 1021 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2015 | 292 | 0.030 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 334 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2013 | 116 | 0.030 |
Why?
|
| ras Proteins | 1 | 2017 | 770 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 503 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 137 | 0.030 |
Why?
|
| Adult | 5 | 2015 | 77950 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| G1 Phase | 1 | 2013 | 285 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 396 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 62 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2003 | 2967 | 0.030 |
Why?
|
| Thrombopoietin | 1 | 2012 | 77 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 4971 | 0.030 |
Why?
|
| Transformation, Bacterial | 1 | 2011 | 16 | 0.030 |
Why?
|
| Histones | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2011 | 82 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2002 | 155 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2011 | 157 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2011 | 122 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2011 | 144 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 1869 | 0.020 |
Why?
|
| Histidine | 1 | 2011 | 91 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 2518 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2011 | 50 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 252 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 568 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 32848 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 995 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 490 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2017 | 1682 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1341 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1529 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 842 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2011 | 220 | 0.020 |
Why?
|
| Mortality | 1 | 2002 | 343 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 886 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 571 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 10001 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 702 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 694 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 1519 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 1618 | 0.020 |
Why?
|
| Cell Division | 1 | 2013 | 2489 | 0.020 |
Why?
|
| Artifacts | 1 | 2012 | 532 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 1121 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 429 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3438 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 1152 | 0.020 |
Why?
|
| Autophagy-Related Protein 8 Family | 1 | 2007 | 4 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2003 | 12873 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 14889 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1859 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 967 | 0.020 |
Why?
|
| Phagosomes | 1 | 2007 | 72 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 966 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 2171 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 878 | 0.020 |
Why?
|
| Plants | 1 | 2007 | 62 | 0.020 |
Why?
|
| Middle Aged | 4 | 2015 | 86204 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 3552 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 731 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 1555 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 769 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2011 | 1203 | 0.020 |
Why?
|
| Peptide Elongation Factors | 1 | 2004 | 17 | 0.020 |
Why?
|
| Peptide Initiation Factors | 1 | 2004 | 45 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2007 | 445 | 0.020 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2004 | 55 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 29902 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 212 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4298 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4053 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 803 | 0.010 |
Why?
|
| Aged | 3 | 2015 | 70117 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 4988 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 6100 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5710 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 9244 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 329 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2001 | 284 | 0.010 |
Why?
|
| Spleen | 1 | 2001 | 676 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 21445 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 13310 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 1016 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 16273 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 3033 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 4143 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2002 | 29154 | 0.010 |
Why?
|
| Incidence | 1 | 2001 | 5673 | 0.010 |
Why?
|